English
Regional settings| Spread | 1.05 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 21.03 |
| Open | 21.18 |
| 1-Year Change | -5.74% |
| Day's Range | 21.18 - 22.46 |
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company. The Company provides physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company markets its three dermatologic products, DecisionDx-Melanoma, DecisionDx-SCC and DecisionDx DiffDx-Melanoma. It also market DecisionDx-UM, a gene expression profiling (GEP) test. It developed and market DecisionDx-Melanoma to healthcare providers for use with patients diagnosed with invasive cutaneous melanoma. It developed DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors. It developed DecisionDx DiffDx-Melanoma, a GEP test designed to be used as an adjunct to histopathology when the distinction between a benign lesion and melanoma is uncertain.
BRIEF: For the fiscal year ended 31 December 2021, Castle Biosciences Inc revenues increased 50% to $94.1M. Net loss increased from $10.3M to $31.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling, General and Administrative. increase of 68% to $70.9M (expense), Research & Development - Balancing value increase from $11.7M to $24.9M (expense).
